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Objectives: Detecting very early markers of neurodegeneration that predate the diagnosis of idiopathic
Parkinson’s disease (PD) is a crucial research topic for the development of disease-modifying therapeutic
interventions. Recently 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy has become widely
used for this purpose, since this test shows high sensitivity and speciﬁcity in the diagnosis of PD, based on
evidence that cardiac sympathetic nerve ﬁbers are affected early and commonly in PD. We reviewed the
literature to determine the role of MIBG myocardial scintigraphy for diagnosing pre-motor PD.
Methods: We performed a systematic review of the literature to identify the use of MIBG myocardial
scintigraphy in relation to the constellation of pre-motor symptoms in PD.
Results: Mild memory disorder, autonomic failure (constipation and postural hypotension), depression/
anxiety, visual hallucination/psychosis (in the elderly), sleep disorder (REM sleep behavior disorder), and
impaired olfaction are reported to appear as sole initial symptoms of PD. All clinical features except for
impaired olfaction are accompanied by low MIBG uptake, suggestive of very early PD in situ.
Conclusion: Identifying persons with mild memory disorder, constipation/postural hypotension,
depression/anxiety, visual hallucination/psychosis (in the elderly), and REM sleep behavior disorder
associated with lowMIBG uptake may provide a unique opportunity to detect very early PD in situwithin
a pre-clinical window. Future prospective studies to investigate further the ﬁndings of these early cases
are warranted.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Parkinson’s disease (PD) is now considered not only a motor dis-
order characterized by parkinsonism, but also a systemic illness with
several non-motor deﬁcits, including: cognitive impairment3; fax: þ81 43 487 4246.
.jp (R. Sakakibara).
r Ltd. Open access under CC BY license(dementia with Lewy bodies [DLB]), depression/anxiety, psychiatric
symptoms, autonomic failure, sleep disorder, and impaired olfaction.
Although there is a close relationshipbetween themotordisorder and
the presence of LB with abnormal a-synuclein aggregation in the
substantia nigra pars compacta (SNC), non-motor deﬁcits are mostly
independent of the SNC pathology, thereby indicating that different
mechanisms converge in the degenerative process. Many non-motor
symptoms appear before the motor symptoms, and are referred to
as ‘pre-motor PD’ [1,2]. This has been conﬁrmed by the careful
following of patients with these pre-motor symptoms they develop.
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Recently, several biomarkers for diagnosing early PD in situ have
become available, such as central dopaminergic depletion by positron
emission tomography (PET) or single-photon computed tomography
(SPECT) [3,4], peripheral noradrenergic depletion by [123I]-meta-
iodobenzylguanidine [MIBG] myocardial scintigraphy [5,6], a-synu-
clein by brain imaging [7,8] and in the cerebrospinal ﬂuid (CSF) [9,10],
and SNC by ultrasound [11] and magnetic resonance imaging (MRI)
[12,13].However, it is not yet knownwhich biomarker is most closely
related to pre-motor PD. In this review, we show, through a review of
the literature, that MIBG may be a helpful non-invasive tool in the
early detection of a patient with pre-motor PD.
2. Method of MIBG myocardial scintigraphy
[123I]-MIBGmyocardial scintigraphywas originally developed to
assess postganglionic presynaptic cardiac sympathetic nerve end-
ings in heart disease including: congestive heart failure, ischemic
heart disease, and cardiomyopathy. Subsequently, cardiac MIBG
uptakewas demonstrated to be reduced in patients with Lewy body
diseases such as PD and DLB and has been reported to be useful for
differentiating PD from other parkinsonisms, as well as DLB from
Alzheimer’s disease (AD). MIBG scintigraphy is based on evidence
that norepinephrine (NE) and MIBG have the same mechanisms for
uptake, storage, and release (Fig. 1) [5]. There are 2 types of NE and
MIBG uptake. Uptake-1 (neuronal uptake), when the concentration
is low, depends on sodium and adenosine triphosphate. Uptake-2
(extraneuronal uptake), which takes place only when the concen-
tration is high, represents simple diffusion. Delayed images are less
dependent on uptake-2, and more accurately reﬂect cardiac sym-
pathetic nerve activity as well as pathology [5,6].
The sensitivity and speciﬁcity of MIBG scintigraphy are high
(near 90%) [14]. Low HM ratio was obtained in 91.3% of Lewy body
diseases (90.0% in PD, 94.1% in DLB, etc). Normal HM ratio was
obtained in 89.1% of disease controls (100% in AD, etc.) [14].
Recently, Tregla et al. [15] and Orimo et al. [16] performed a meta-
analysis on the sensitivity and speciﬁcity of MIBG scintigraphy.
Tregla et al. [15] analyzed 19 studies comprising 1972 patients
(1076 patients with PD, 117 patients with other Lewy body diseases
and 779 patients with other Non neurological diseases). The pooled
sensitivity of MIBG scintigraphy in detecting PD was 88% (95% CIFig. 1. Representative cases of 123I-MIBG myocardial scintigraphy. A: normal control (HM
iodobenzylguanidine The HM ratio: the heart to mediastinum ratio The cut-off value of delay
uptake], reﬂecting cardiac sympathetic nerve activity) of the HM ratio was 2.0. A reduced86e90%); the pooled speciﬁcity of MIBG scintigraphy in discrimi-
nating between PD and other parkinsonisms was 85% (95% CI 81e
88%). The area under the ROC curve was 0.93. Similarly, Orimo et al.
[16] analyzed 13 studies comprising 845 patients including 625 PD
and 220 other neurodegenerative parkinsonism. The pooled
sensitivity to differentiate PD from other neurodegenerative par-
kinsonisms by a delayed heart-to-mediastinum (HM) ratio was
89.7% and the speciﬁcity was 82.6%.
As a factor affecting the HM ratio, patients withmild Hoehn Yahr
stage or short-duration disease may have myocardial MIBG ab-
normality less frequently. However, according to Orimo et al. [16],
when PD was limited to early stage (Hoehn-Yahr stage 1 or 2), the
pooled sensitivity by delayed H/M ratio was as high as 94.1% and
the speciﬁcity was 80.2%. PD patients with longer duration may
have more frequent myocardial MIBG abnormality. Satoh et al. [17]
have estimated the yearly reduction rate of the HM ratio to be 0.02.
Another factor might be that dopamine or its precursor DOPA
might act as a competitive inhibitor of NE transporter-mediated
MIBG uptake. Experimental studies have shown that MIBG up-
take is inhibited by NE, more so by dopamine, and to a lesser extent
by DOPA and serotonin in neuroblastoma cells that lack dopamine
and serotonin uptake systems [18]. In healthy humans and in early-
phase PD, levodopa might affect MIBG uptake [19,20].
2.1. Memory disorder
Early differential diagnosis of memory disorder is a challenge for
neurologists. In contrast to the focus on early-stage AD [21,22], little
is known about early-stagememory disorder in dementiawith DLB,
a Lewy body disease. Mild cognitive impairment (MCI) is a condi-
tion that is described as being not normal for age yet not demented
(does not meet criteria (DSM IV, ICD 10) for a dementia syndrome);
presence of cognitive decline based on self and/or informant report
and progressive impairment on objective cognitive tasks; and
essentially preserved basic activities of daily living [23]. In addition,
amnestic MCI is diagnosed by the presence of impairment in
memory [23]. It is important to identify MCI patients with a higher
risk of progression to dementia (10e15% per year), since early
treatment might delay disease progression [21,22]. Identifying the
causes of MCI is not easy, though individual management depends
on the cause. It is now acknowledged that DLB may produce a wideratio 2.84), B: a case of abnormal low accumulation (HM ratio 1.41). MIBG: meta-
ed MIBG images (4 h after injection of 111 MBq MIBG, depending on uptake-1 [neuronal
HM ratio indicates peripheral noradrenergic depletion.
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neous parkinsonism (the core clinical features), together with
depression, sleep disorder, and autonomic disorder [24]. Regarding
LB pathology, approximately 8e17% of neurologically normal sub-
jects over 60 years of age have LB on postmortem examination,
referred to as incidental LBD [25]. Some pathology-proven LBD
patients have shown amnestic MCI before progressing to the core
clinical features of DLB (dementia and spontaneous parkinsonism)
[26]. However, it is regarded as difﬁcult to diagnose these early-
stage DLB patients before they develop the full clinical spectrum.
Using MIBG scintigraphy, Fujishiro et al. recently reported two
patients with a clinical diagnosis of amnestic MCI who had low
MIBG uptake, without the core clinical features of DLB [27]. One
patient, a 75-year-old male, had episodes of RBD, visual halluci-
nation, and spontaneous parkinsonism two years after amnestic
MCI was diagnosed. The other patient, a 62-year-old female,
developed amnestic MCI, and had occipital hypo-metabolism on an
18F-ﬂuoro-D-glucose PET. Neither patient had diabetes nor a car-
diac condition that might affect the MIBG uptake.
During a 3-year period, 254 patients with memory complaints
attended our university neurology clinic: 106 men, 148 women;
mean age 72.5 years (48e95 years). All patients underwent a
neurological examination; cognitive testing including the Mini
Mental-State Examination (MMSE; 0e30 scale, normal > 24), the
Alzheimer’s Disease Assessment Scale‒Cognitive Behavior Section
(ADASecog; 0e70 scale, normal < 10), the Frontal Assessment
Battery (FAB; 0e18 scale, normal > 16), and the Wechsler Memory
Scale Revised (WMS-R) if detailed assessment of memory becomes
necessary; a brain MRI to check for hippocampal atrophy by VSRAD
(Voxel-based Speciﬁc Regional analysis system for AD) MRI
morphometry software; and 99mTc-L,L-ethylcysteinate dimer (ECD)
SPECT. In addition, we performed MIBG scintigraphy with the
method described earlier in this paper. The cut-off value of delayed
MIBG images of the heart-to-mediastinum (HM) ratiowas 2.0. None
of the subjects had heart failure or diabetic neuropathy, and none
was taking serotonergic or any other drugs thatmight interferewith
MIBG scintigraphy. Among the 254 patients, 44 patients were
diagnosed with amnestic MCI; and 13 of 44 cases (30%) showed low
MIBGuptake. Noneof the 13patients had the core clinical features of
DLB [28]. The sensitivity and speciﬁcity of MIBG scintigraphy were
high (around90%). Asdescribedabove, lowHMratiowasobtained in
91.3% of Lewybody diseases (90.0% in PD, 94.1% in DLB, etc.). Normal
HMratiowas obtained in 89.1% of diseases control (100% in AD, etc.).
None of the 13 patients had comorbid diseases or were taking drugs
thatmight affectMIBGuptake. Therefore, ifweaccept reducedMIBG
uptake as a biomarker, these patients most probably had LB pa-
thology. The 13 patients had the following clinical characteristics:
they were uniformly elderly (mean age 78.9 years, 70e84 years),
with an equal sex ratio (7 male, 6 female), and had relatively slow
progression (meanduration ofmemorydisorder at presentation, 3.8
years, 1e7 years) and preserved general cognitive function (mean
MMSE 24.8, 21‒30; mean ADAScog 12.2, 6e20).
In addition to memory impairment, these patients commonly
showed slowed frontal executive function by FAB (12.5/18, 8e15)
[29,30] and 5 had mild visual hallucinations; therefore, they were
regarded as multidomain amnestic MCI. Other than memory dis-
order, they had various autonomic disorders (nocturia in 7, urinary
incontinence in 2, constipation in 2, postural hypotension in one),
REM [rapid-eye movement] sleep behavioral disorder (in 3), and
occipital hypoperfusion by ECD-SPECT (in 5) [31,32]. These features
are rare in AD, but are commonly reported in combination with, or
as isolated features of, DLB as described below. This cohort of
multidomain amnesticMCI casesmay eventually presentwith early
stage DLB because of the presence of low MIBG uptake. Clinically,
many of them have slowed frontal executive function, and somehave visual hallucinations and autonomic and sleep disorders,while
some do not. Therefore, in cases such as these, MIBG scintigraphy
may be particularly helpful in differentiating early-stage DLB from
early-stage AD before full clinical features appear.
2.2. Autonomic failure
2.2.1. Constipation
Constipation is a common symptom in the geriatric population.
It may occur after loss of dietary ﬁber consumption and reduction
of physical exercise. Rare causes include smooth muscle myopathy,
vasculitic neuropathy, amyloidosis, mitochondrial disease, etc [33].
As for PD, the Honolulu Heart Program that followed-up for inci-
dental PD over a 24-year period showed that infrequent bowel
movements are associated with an elevated risk of PD [34]. Also,
pathology-proven cases with SNC loss an7d LBs have been shown
to have been constipated [35]. However, it is regarded as extremely
difﬁcult to diagnose such early-stage PD patients on this basis
alone. Recently, we examined ﬁve such patients [36].
Among 1600 outpatients, only ﬁve patients fulﬁlled our estab-
lished criteria. The inclusion criteria were: constipation deﬁned as
fewer than 3 bowel movements per week, regular laxative use, and/
or difﬁcult defecation; and low HM ratio (<2.0) in the delayed
images of MIBG scintigraphy. Among these, we excluded apparent
motor disorder indicating PD, apparent neurologic diseases other
than PD, apparent gastrointestinal diseases, and drugs that might
affect bowel function or MIBG uptake. We administered the
quantitative lower-gastrointestinal autonomic test (QL-GAT) to the
patients to explore the mechanism of constipation. We also per-
formed polysomnographic, cognitive, autonomic, and imaging tests
to the greatest extent possible. Most of the patients were referred
from a gastroenterology clinic for elucidation of the neurologic
etiologies of their constipation. They were uniformly elderly (mean
age, 68 years; range 60e81 years) and male. All patients walked
independently. All patients had decreased bowel frequency and
difﬁculty defecating with a mean duration of difﬁculty of 4.8 years
(range 2e10 years).
In addition to a complaint of constipation, these patients
showed relatively mild dysfunction by the QL-GAT: namely, case 1,
normal; case 2, low resting anal pressure alone; case 3, decreased
rectal sensation, decreased rectal contraction, anismus, and post-
defecation residual; case 4, slowed total colonic transit time
(CTT); and case 5, slowed total CTT and post-defecation residual.
Four patients reported REM sleep behavioral disorder (RBD), which
started simultaneously with bowel dysfunction in 3 cases, and 2
years after the onset of bowel dysfunction in one. Bladder
dysfunction was noted in 4 cases. Transient hallucinations were
noted in two. None of the 5 patients had abnormalities as shown on
MRI. Three of 4 patients revealed occipital hypoperfusion by SPECT.
During the 3 year follow-up period, one patient developed mild
muscle rigidity and unilateral postural tremor. These symptoms
responded to treatments.
As shown above, ‘constipation and MIBG abnormality’ is clini-
cally different from typical PD, in terms of a lack of motor features,
uniformly elderly subjects, and relativelymild bowel dysfunction in
the QL-GAT. In contrast, the similarities included RBD, bladder
dysfunction [37], occipital hypoperfusion and hallucination.
Considering the high sensitivity and speciﬁcity of MIBG abnor-
mality for the diagnosis of PD, it seems likely that constipation and
MIBG abnormality can be regarded as initial manifestations of PD.
Pathological studies have shown degeneration and Lewy neurites
in the myenteric plexus in PD [38], which may predate LB in the
central nervous system [39]. Although rare, PD can be a cause of
constipation in the general geriatric population, and some of these
patients might later develop amotor disorder. Clinically, four of ﬁve
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frontal executive function, visual hallucination, RBD, bladder
dysfunction, and occipital hypoperfusion), one had not. Therefore,
in such cases, MIBG scintigraphy may be helpful in alerting the
physician to early-stage DLB before full clinical features appear. In
addition, in order to manage constipation in the elderly, neurologic
observation may be needed as a matter of course.2.2.2. Postural hypotension
Syncope is not uncommon in the normal population. It is
derived from cardiogenic causes (arrhythmias, e.g., paroxysmal
atrial ﬁbrillation, long QT syndrome etc. and structural heart dis-
eases, e.g., aortic stenosis etc.) and neurogenic causes (neurally
mediated syncope [NMS] and postural hypotension). Among
neurogenic causes NMS is the most common [40,41]. NMS, also
known as reﬂex syncope, is a systemic vasodilatation with variable
degrees of bradycardia. NMS frequently has a characteristic history
that includes premonitory symptoms (yawning, epigastric
discomfort, nausea, visual disturbances), and typical appearance
(pallor, sweating) and trigger situations (strong emotions, unex-
pected pain, prolonged standing). NMS is benign, and patients only
need to be reassured or recommended to perform regular exercise
and maintain their ﬂuid intake.
Postural hypotension is less common than NMS, but leads to a
signiﬁcant burden and morbidity in patients. Postural hypotension
is a failure of reﬂex vasoconstriction in the lower half of body,
leading to sustained reduction of systolic blood pressure by at least
20 mmHg, within 3 min of standing or head-up tilt to 60 on a tilt
table. Postural hypotension often accompanies numbness of feet
(diabetic neuropathy etc.) or gait difﬁculty with urinary dysfunc-
tion (multiple system atrophy, a disease that preferentially affects
the spinal sympathetic preganglionic cells). When postural hypo-
tension appears with no other neurological features, usually with
evidence of more widespread autonomic failure [42,43], it is called
pure autonomic failure (PAF, a disease that affects peripheral
sympathetic vasomotor ﬁbers). Although PAF lacks other neuro-
logical features in its deﬁnition, an over-10-year follow-up showed
that some PAF patients developed the full clinical manifestation of
DLB [44]. Also, pathology studies of PAF cases showed the presence
of alpha-synuclein-positive Lewy neurites in the peripheral sym-
pathetic nerves, suggesting that PAF is an early-stage PD [45].
However, it is regarded as difﬁcult to diagnose such early-stage PD
patients on this basis alone.
Yoshida et al. [46] and Kashihara et al. [47] showed reduced
MIBG uptake in PAF. Therefore, it seems that PAF is a condition
suggesting a future risk of PD. More recently, Goldstein et al. [48]
reported a PAF patient with abnormal cardiac uptake of ﬂuo-
rodopamine at a time when brain ﬂuorodopa uptake was normal.
Four years later he developed dementia and parkinsonism together
with abnormal ﬂuorodopa uptake. In this case, neuroimaging evi-
dence of cardiac noradrenergic denervation and subsequent pro-
gressive striatal dopaminergic denervation ﬁt with Braak staging.
Bladder and sexual dysfunction are rarely the initial feature of PAF
[42]. This is in contrast to multiple system atrophy (MSA), which
presents with bladder and sexual dysfunction as sole initial mani-
festations [49,50]. This is important since some MSA may present
with chronic autonomic failure alone without motor features. A
recent paper showed that among 29 autopsy-proven MSA cases,
two had been clinically misdiagnosed with PAF [51]. Therefore,
particularly in such cases, MIBG scintigraphy may help with the
differential diagnosis between early-stage DLB and early-stage
MSA. In contrast to lesions in the postganglionic sympathetic
nerve ﬁbers in PAF [45], preganglionic spinal sympathetic neurons
are affected in MSA [51].2.3. Depression/anxiety
Depression is a common psychiatric illness with a prevalence of
around 6% in the general population. It is characterized by feelings
of sadness and despair, and causes signiﬁcant morbidity [52].
Anxiety- and stress-related disorders are also common, with esti-
mated prevalences ranging from 2 to 20% in the general population.
These disorders are characterized by excessive worry and irrita-
bility associated with symptoms of depression [53]. Depression/
anxiety causes not only psychiatric but also physical changes,
including insomnia, anorexia, tachycardia, and sexual, bowel and
bladder dysfunction [54]. It has recently been recognized that
depression/anxiety may precede various neurodegenerative dis-
eases such as AD and PD [55].
Depression is the most common psychiatric disorder in PD. Es-
timates of the prevalence range, from 2.7 to 76%, with an average
prevalence of about 35% [56]. Factors consistently correlated with
depression in PD include early-onset PD, advanced stage PD, female
gender, anxiety, cognitive impairment, and psychosis [55]. Patho-
logic degeneration of mesolimbic dopamine, norepinephrine, and
serotonergic pathways in conjunctionwith degeneration of orbitale
frontal circuits and subcortical structures, such as the locus coeru-
leus, dorsal raphe nuclei, and ventral tegmental area, are postulated
to be associated with the development of depressive symptoms
[57]. Interestingly, Kim et al. found no correlation between seroto-
nergic dysfunction and depressive symptoms in patients with PD,
but rather, evidence that the dysfunction of noradrenergic and
limbic monoaminergic projections was associated with depression
[58]. Several studies have reported that depressionmay precede the
onset of PD [57,58]. However, it is regarded as too difﬁcult to identify
such early-stage PD patients, before they develop the motor
symptoms. Kobayashi et al. recently described a set of 10 patients
with late-onset major depression and 3 patients with late-onset
generalized anxiety [36]. The mean ages at onset and at ﬁrst visit
were 66.7 for the 10 late-onset major depression patients and 69.7
years for the 3 patients with generalized anxiety disorders. None of
them showed parkinsonian motor features or cognitive decline at
the ﬁrst visit. In addition to depression/anxiety, two patients had
repeated episodes of transient amnesia. One had REM sleep
behavioral disorder (RBD). Among the 8 cases who underwent
SPECT scans, decreased cerebral perfusion was found in the frontal
lobe in 5 and the occipital lobe in one. All 13 cases showed reduced
MIBG uptake. Eleven of 13 cases later developed symptoms of PD.
These ﬁndings support the hypothesis that depression constitutes
an early manifestation of PD. To the best of our knowledge, no
studies have reported the frequency of positive MIBG among older
subjects presentingwith depression; however, considering the high
frequency (8e17%) of incidental LBD at autopsy [25], premotor PD
with depression alone might be not rare.
2.4. Visual hallucination/psychosis in the elderly
Psychosis is a common psychiatric symptom characterized by
hallucinations and delusions. In community-based samples the
estimated prevalence of psychosis in the elderly ranges widely,
from 0.2% to 4.75%, and as high as 10e63% in nursing home pop-
ulations [57,58]. In the elderly, causes may include: schizophrenia,
affective illnesses, delirium, substance intoxication, AD, fronto-
temporal dementia (FTD), and PD. Among these, it is well docu-
mented that FTD patients present with behavioral abnormalities
and psychosis without cognitive decline in the early stage of the
illness [59]. Progressive aphasia without dementia, or semantic
dementia, also appears as a clinical manifestation of FTD [60]. Vi-
sual hallucinations in the elderly, without dementia or behavioral
changes, may occur early in PD/DLB. The biological substrates that
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stood. In PD/DLB cases, the mesocortical/mesolimbic areas and
basal ganglia (ventral tegmental area and ventral striatum) might
be the anatomical substrates [61], and increased visual cortical
excitability has also been suggested [62]. Recently, Kobayashi et al.
described 4 elderly patients with visual hallucination [36]. Their
age at ﬁrst visit was 79e81 years. In addition to visual hallucina-
tions, all four patients had cognitive difﬁculties in daily life, and
MMSE scores ranging from 20 to 26/30. One of them had
constructional apraxia. However, parkinsonian motor signs were
completely absent in all four cases. All patients showed occipital
hypoperfusion SPECT scan. Two had REM sleep behavior disorder.
All four cases showed reducedMIBG uptake. These ﬁndings support
the hypothesis that visual hallucinations are a future risk for PD.2.5. Sleep disorder
Parasomnias and sleep-talking are not uncommon in early
childhood, but subside in adulthood [63,64]. They also appear in
older adults, and rapid eye movement (REM) sleep behavior dis-
order (RBD) has been extensively studied in this group. Patients
with RBD appear to be acting out their dreams while in REM sleep.
The behaviors are typically violent, in association with violent
dream content, so that the patient or the bed partner may suffer
serious harm. The estimated prevalence of sleep disorders in adults
is 0.4e0.5% [65], but the frequency is much higher in certain
neurodegenerative diseases, particularly PD, DLB, and MSA [66].
The mechanism of RBS??? is still not entirely clear. However, ani-
mal models and cases of RBD developing after brainstem lesions
(pontine tegmentum including locus ceruleus, medulla) have led to
the understanding that RBD is caused by a lack of normal REM
muscle atonia and a lack of normal suppression of locomotor
generators during REM [66].
RBD can occur in the absence of neurologic diseases (the
“idiopathic” form), although patients with this form of RBD may
ultimately develop full motor signs of PD [67]. Also, an autopsy-
proven case with cell loss in the locus ceruleus and the substantia
nigra and LB had a history of RBD [68]. However, it is regarded as
difﬁcult to diagnose such early-stage PD patients before further
symptoms appear. Recently, several reports have described low
MIBG uptake in idiopathic RBD patients without parkinsonian
motor features [69,70]. Among these, Kashihara et al. [70] reported
that cardiac sympathetic denervation is more severe in RBD than in
early PD. This suggests that RBDmay not simply be a premotor form
of PD, but that it may be associated with more widespread changes
than are seen in mild PD. In addition, a recent imaging study
indicated that cardiac denervation precedes nigrostriatal damage in
RBD patients [71]. These ﬁndings support the hypothesis that RBD
constitutes a future risk for PD.2.6. Impaired olfaction
A decreased sense of smell can lead to signiﬁcant impairment of
quality of life, including taste disturbance and loss of pleasure from
eating with resulting changes in weight and difﬁculty in avoiding
health risks such as spoiled food or not recognizing a natural gas
leak. Recent epidemiological reports have shown that when vali-
dated smell identiﬁcation or threshold tests are used, they reveal
quite a high prevalence of hyposmia and anosmia in the elderly
[72]. Several pathophysiologic processes have been postulated for
these phenomena, including: aging, olfactory receptor genes, toxic
exposures/drugs, head trauma, systemic viral infection, autoim-
munity, rhinosinusitis, and neurologic diseases such as cerebro-
vascular disease, AD, and PD [72e75].In PD, a recent survey showed that the prevalence of hyposmia
in PD is 13.4% (669 among 4999 PD cases) [76]. Recent imaging
studies showed decreased olfactory bulb volume in PD patients by
3.0-Tesla MRI [77]. It has been well documented that LB pathology
ﬁrst affects the anterior olfactory nucleus and lower brainstem
nuclei (Stage 1 according to Braak and colleagues) [78], suggesting
that hyposmia is an early symptom/sign in PD. However, it is
regarded as difﬁcult to diagnose such early-stage PD patients on
this basis alone. At this time there are no studies that have inves-
tigated whether hyposmia is related to low MIBG uptake. In
contrast, hyposmia has been documented in idiopathic REM sleep
behavior disorder (RBD) as described above [79]. Since it is known
that some patients with idiopathic RBD may develop the full clin-
ical manifestation of PD, the relationship between hyposmia alone
and low MIBG uptake is worth investigating in the future.
'Finally, we address the Braak hypothesis and MIBG myocardial
scintigraphy. In 2003 Braak et al. [78] reported that the pathological
lesions initially occur in the dorsal vagal motor nucleus of the
brainstem and olfactory nucleus in the brain. Thereafter, the disease
process in the brainstem pursues an ascending course to the mes-
ocortex and the neocortex. This pathological perspective was
reproduced by other investigators. Recent studies focusing on
incidental Lewybody disease (ILBD) revealed not only brain but also
peripheral LB pathology exist, including cardiac sympathetic nerves
and those of the conduction system [80e82]. However, a fewstudies
reported peripheral involvement in the absence of LB pathology in
the brain, e.g., sympathetic cardiac nerves [83], or sympathetic
cardiac nerves and the stellate ganglion [84], it cannot be entirely
ruled out that the pathological process may begin in the peripheral
autonomic system [85]. In light of the present review, sympathetic
cardiac denervation may occur very early with mild memory dis-
order/psychosis in elderly patients (cortical lesion), constipation
(peripheral myenteric plexus), postural hypotension (peripheral
vasomotor), depression/anxiety (limbic monoaminergic etc.), and
REMsleep behavior disorder (locus ceruleus etc.), before developing
amotor disorder [48]. MIBGmyocardial scintigraphymay provide a
way to detect early PD in situ within a pre-clinical window.
3. Conclusion
Identifying persons with mild memory disorder; constipation/
postural hypotension; depression/anxiety; visual hallucination/
elderly psychosis; and REM sleep behavior disorder who also show
low MIBG uptake may provide a way to detect early PD in situ
within a pre-clinical window. Future prospective studies to follow-
up these cases will clarify the diagnostic power of MIBGmyocardial
scintigraphy in detecting pre-motor PD.
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